Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The company said it plans to submit a Formal Dispute Resolution Request to the FDA over reproxalap for dry eye disease. Aldeyra also said it now expects operational cash runway into 2029 based on reported cash and cash equivalents of $45.1 million as of June 30, 2026.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDR…
Aldeyra Therapeutics announced its intent to submit a formal dispute resolution request for reproxalap to treat dry eye disease.